Supplementary Figure S2 from Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer

Figure S2. Reduction in FES uptake as measured by mean percent change from baseline in background-corrected maximum standardized uptake value indicates target engagement and robust reduction in ER activity across all doses. The asterisks indicate patients with baseline ESR1 mutations. (A) FES-PET scans demonstrating FES-avid disease at baseline and reduced FES uptake on treatment in patients treated with 90 mg (left) and 250 mg giredestrant (right) (B).